Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 17Gastrointestinal 2Thoracic 1Plasma cell 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 220Head and Neck Neoplasms 172Carcinoma, Non-Small-Cell Lung 104Melanoma 63Neoplasms 56Colorectal Neoplasms 55Uterine Cervical Neoplasms 53Ovarian Neoplasms 50Stomach Neoplasms 48Neoplasm Metastasis 46Breast Neoplasms 46Triple Negative Breast Neoplasms 45Lung Neoplasms 44Carcinoma, Renal Cell 40Esophageal Neoplasms 37Nasopharyngeal Carcinoma 33Endometrial Neoplasms 33Pancreatic Neoplasms 32Thyroid Neoplasms 30Prostatic Neoplasms 26Carcinoma, Squamous Cell 26Sarcoma 25Colonic Neoplasms 24Urinary Bladder Neoplasms 23Small Cell Lung Carcinoma 23Oropharyngeal Neoplasms 23Carcinoma, Transitional Cell 23Carcinoma 22Salivary Gland Neoplasms 20Nasopharyngeal Neoplasms 20

Interventions

cemiplimab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Liposarcoma × Head & Neck × Clear all
NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

OncoResponse, Inc.

Phase 1/2 Unknown
172 enrolled
DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡